Comparative Pharmacology
Head-to-head clinical analysis: METANDREN versus VIRILON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METANDREN versus VIRILON.
METANDREN vs VIRILON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Androgen receptor agonist; binds to androgen receptors in target tissues, activating gene transcription and promoting protein synthesis, growth of male reproductive organs, and secondary sexual characteristics.
Testosterone replacement therapy; binds to androgen receptors, leading to activation of androgen-responsive genes and promotion of male secondary sexual characteristics.
Oral: 5-25 mg once daily for testosterone replacement therapy in adult males.
200 mg intramuscularly every 2 weeks for androgen replacement therapy in adult males.
None Documented
None Documented
The terminal elimination half-life of methyltestosterone is approximately 3-4 hours. This short half-life necessitates multiple daily dosing (e.g., 10-50 mg orally 1-3 times daily) to maintain therapeutic androgen levels. However, due to its oral administration and first-pass metabolism, the clinical effect may last longer.
Terminal elimination half-life is approximately 3–4 hours for methyltestosterone; however, the pharmacologic effect persists longer due to active metabolites, supporting once-daily dosing.
Metandren (methyltestosterone) is primarily metabolized in the liver and excreted in the urine as glucuronide and sulfate conjugates. Approximately 90% of a dose is excreted renally, with less than 5% eliminated via feces. Biliary excretion is minimal.
Approximately 90% of administered methyltestosterone is excreted as glucuronide and sulfate conjugates in urine; less than 5% appears in feces as unchanged drug and metabolites.
Category C
Category C
Androgen
Androgen